Hill AM - Search Results

1

Rebound of HIV-1 viral load after suppression to very low levels.

Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN. Staszewski S, et al. Among authors: hill am. AIDS. 1998 Dec 3;12(17):2360. AIDS. 1998. PMID: 9863886 No abstract available.

2

CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.

Phillips AN, Youle M, Lampe F, Sabin CA, Hill A, Ransom D, Gumley H, Loveday C, Lipman M, Johnson M. Phillips AN, et al. AIDS. 2002 May 3;16(7):1073-5. doi: 10.1097/00002030-200205030-00016. AIDS. 2002. PMID: 11953476 No abstract available.

3

Designing and interpreting HIV noninferiority trials in naive and experienced patients.

Hill A, Sabin C. Hill A, et al. AIDS. 2008 May 11;22(8):913-21. doi: 10.1097/QAD.0b013e3282f5556d. AIDS. 2008. PMID: 18453850 Review. No abstract available.

4

Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.

Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Staszewski S, et al. Among authors: hill am. AIDS. 1997 Mar 15;11(4):477-83. doi: 10.1097/00002030-199704000-00011. AIDS. 1997. PMID: 9084795 Clinical Trial.

5

HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors.

Staszewski S, DeMasi R, Hill AM, Dawson D. Staszewski S, et al. Among authors: hill am. AIDS. 1998 Oct 22;12(15):1991-7. doi: 10.1097/00002030-199815000-00010. AIDS. 1998. PMID: 9814867

6

HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.

Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, Self P, Hill AM. Phillips AN, et al. Among authors: hill am. AIDS. 1996 Jul;10(8):859-65. doi: 10.1097/00002030-199607000-00009. AIDS. 1996. PMID: 8828743 Clinical Trial.

7

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.

Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM. Phillips AN, et al. Among authors: hill am. AIDS. 1997 Feb;11(2):169-75. doi: 10.1097/00002030-199702000-00006. AIDS. 1997. PMID: 9030363

8

Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Chancellor JV, et al. Among authors: hill am. Pharmacoeconomics. 1997 Jul;12(1):54-66. doi: 10.2165/00019053-199712010-00006. Pharmacoeconomics. 1997. PMID: 10169387

9

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H. Katlama C, et al. Among authors: hill am. JAMA. 1996 Jul 10;276(2):118-25. JAMA. 1996. PMID: 8656503 Clinical Trial.

10

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H. Staszewski S, et al. Among authors: hill am. JAMA. 1996 Jul 10;276(2):111-7. JAMA. 1996. PMID: 8656502 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters